Oppenheimer analyst Hartaj Singh lowered the firm’s price target on Eloxx Pharmaceuticals to $50 from $120 post-reverse split, while keeps an Outperform rating on the shares. The analyst notes Eloxx reported Q3 financial/research updates, and its stock started to trade on a 1-for-40 reverse split basis in December 22.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ELOX: